<a href="https://www.fiercebiotech.com/biotech/ada-tolerability-not-be-underappreciated-roche-zealands-amylin-obesity-prospect" hreflang="en">ADA: Tolerability ‘not to be underappreciated’ in Roche, Zealand’s amylin obesity prospect</a>
At the American Diabetes Association 2026 Scientific Sessions, Zealand Pharma and Roche presented new data on their amylin analog, petrelintide, highlighting its promising tolerability and weight loss results from the midphase ZUPREME-1 trial, which showed a 10.7% mean weight reduction and a favorable side effect profile. The companies plan to initiate a phase 3 program for petrelintide later in 2026, emphasizing its potential as a new option in obesity treatment amidst a competitive market.
Zealand Pharma and Roche's petrelintide shows promise in obesity treatment, with a distinct tolerability profile that could improve patient adherence, a critical factor in the effectiveness of obesity medications. The midphase ZUPREME-1 trial data highlights a 10.7% mean weight loss over 42 weeks and a low discontinuation rate due to gastrointestinal side effects, suggesting potential for this amylin analog to meet a significant unmet need in the market. Roche plans to launch a phase 3 program in the latter half of 2026, indicating a potential investment opportunity as they aim to become a top player in the obesity drug market.